TABLE 13.

Results of the selected studies examining T cell immunotherapy in treating ovarian cancer.

Name of the study	Year of the study	Phase of the study	Research group	Dose	Results
Kershaw et al. (Kershaw et al., 2006)	2006	I	14	3 × 109–5 × 1,010 transduced T cells	There were observed some grade 3 and 4 toxicities in the group with high-dose usage of IL-2; in the group, which received T cells without IL-2, patients experienced relatively mild side effects; there was not observed any tumor burden in patients
Dobrzanski et al. (Dobrzanski et al., 2012)	2012	Phase I/II	7	108–109 T cells per infusion (i.e. 1–4 × 108 cells/m2)	There was observed enhanced patient survival in 3 monthly treatment cycles (3->84 months)

IL, interleukin.